SARS-CoV-2 viral load is associated with increased disease severity and mortality

The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely undefined in coronavirus disease 2019 (COVID-19). Here, we quantify SARS-CoV-2 viral load from participants with a diverse range of COVID-19 disease severity, including those requiring hospitalization, outpatients with mild disease, and individuals with resolved infection. We detected SARS-CoV-2 plasma RNA in 27% of hospitalized participants, and 13% of outpatients diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, we report that a higher prevalence of detectable SARS-CoV-2 plasma viral load is associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality. Our data show that SARS-CoV-2 viral loads may aid in the risk stratification of patients with COVID-19, and therefore its role in disease pathogenesis should be further explored.
Although coronavirus disease 2019 (COVID-19) has affected more than 20 million cases worldwide, wide gaps remain in our knowledge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis, including the relationship between levels of viral replication and disease severity. In prior analyses of the SARS-CoV-1 outbreak, viral load within the nasopharynx was associated with worsened disease severity and increased mortality\textsuperscript{1-3}. However, it is also clear that there are significant differences between SARS-CoV-1 and 2, including differences in the temporal nature of viral shedding\textsuperscript{4,5}, transmissibility\textsuperscript{6}, epidemiology\textsuperscript{7,8}, and clinical manifestations\textsuperscript{9-13}. Additional studies are needed to determine whether the degree of SARS-CoV-2 viral load within the respiratory tract or other compartments may predict disease outcomes.

The need for additional SARS-CoV-2 viral studies is not only limited to respiratory specimens but extends to the blood. Respiratory failure is the primary cause of death in patients with COVID-19, but complications arising from a hyperactive immune response and vascular damage are also prominently featured both in the pulmonary and extrapulmonary systems\textsuperscript{9}. In addition, there is a suggestion that detectable plasma viremia using a qualitative viral detection assay may correlate with disease severity\textsuperscript{14}, although studies to date have been hampered by the lack of viral load quantification. Together, these findings suggest the importance of systemic SARS-CoV-2 viral circulation but little is known about the prevalence and magnitude of plasma viremia in predicting COVID-19 outcomes. In this study, we quantify SARS-CoV-2 viral load from the respiratory tract, plasma and urine of participants with a diverse range of COVID-19 severity, including individuals requiring hospitalization, symptomatic non-hospitalized participants, and those recovered from COVID-19 disease. Here we show that SARS-CoV-2 viral loads, especially in the plasma, are predictive of mortality.

**Table 1 Demographics and clinical characteristics of participants at baseline.**

| Characteristic | Hospitalized (N = 88) | Symptomatic non-hospitalized (N = 90) | Recovered (N = 53) |
|---------------|-----------------------|--------------------------------------|-------------------|
| Female sex, % | 38%                   | 62%                                  | 65%               |
| Age, median years [Q1,Q3] | 57 [43,68] | 48 [31,59] | 33 [29,42] |
| Ethnicity | | | |
| Caucasian | 35% | 79% | 81% |
| Black/African | 15% | 8% | 6% |
| American | | | |
| Hispanic/Latino | 38% | 3% | 6% |
| Other | 12% | 10% | 8% |
| Comorbidities | | | |
| Hypertension | 53% | 22% | 2% |
| Chronic Lung | 18% | 30% | 2% |
| Disease | | | |
| Diabetes | 40% | 11% | 2% |
| BMI | | | |
| <25 | 20% | 35% | 62% |
| 25–29.99 | 35% | 24% | 24% |
| ≥30 | 45% | 40% | 14% |
| Days between symptom onset and initial sample collection, median [Q1,Q3] | 13 [10,18] | 5 [2,15] | 27 [20,34] |
| Oxygenation status at time of enrollment | | | |
| Room air | 15% | | |
| Nasal cannula | 37% | | |
| Ventilator | 48% | | |
| Hospitalization status | | | |
| % Discharged | 85% | | |
| % Mortality | 13% | | |

**Results**  

**Participant characteristics and SARS-CoV-2 viral loads.** We enrolled 88 hospitalized participants with COVID-19, 94 symptomatic individuals who were evaluated in a respiratory infection clinic, of whom 16 were diagnosed with COVID-19 by standard clinical testing of nasopharyngeal swabs, and 53 participants diagnosed with COVID-19, who had symptomatically recovered. Table 1 shows baseline demographic information, disease severity, and hospital outcomes. Hospitalized participants were significantly older than both symptomatic outpatients and individuals recovered from COVID-19 (Kruskal–Wallis P < 0.001). Participants recruited in the outpatient setting had the shortest time between the start of symptoms and the time of sample collection (median 5 days) compared to hospitalized individuals (median 13 days) and recovered participants (median 27 days). Eleven of the hospitalized participants were treated with remdesivir during their hospitalization (Supplementary Fig. 1).

We report SARS-CoV-2 viral load analysis, both as a continuous variable and analyzed as a categorical variable (detectable vs. undetectable) given that only qualitative commercial viral detection assays are currently available for clinical care. Among hospitalized individuals, the majority still had detectable SARS-CoV-2 RNA at the time of initial sample collection, including 50% with detectable SARS-CoV-2 RNA by nasopharyngeal swab, 67% by oropharyngeal swab, and 85% by sputum testing. We also performed SARS-CoV-2 viral load testing from specimens outside of the respiratory tract and found that 27% of participants had detectable SARS-CoV-2 plasma viremia and 10% had detectable viral RNA in the urine (Fig. 1). In those with detectable plasma viremia, the median viral load was 2.4 log\textsubscript{10} RNA copies/mL (range 1.8–3.8 log\textsubscript{10} RNA copies/mL), which was significantly lower than that detected in sputum (median 4.4 log\textsubscript{10} RNA copies/mL, range 1.8–9.0 log\textsubscript{10} RNA copies/mL, Wilcoxon signed-rank P < 0.001).

Levels of SARS-CoV-2 viral load were significantly correlated between each of the different respiratory specimen types (nasopharyngeal vs oropharyngeal Spearman’s r = 0.34, P = 0.03; nasopharyngeal vs. sputum r = 0.39, P = 0.03, oropharyngeal vs. sputum r = 0.56, P = 0.001, Supplementary Fig. 2). Plasma viral load was modestly associated with both nasopharyngeal (r = 0.32, P = 0.02) and sputum viral loads (r = 0.36, P = 0.049), but not significantly associated with oropharyngeal viral loads. There was no significant association between urine viral load and viral loads from any other sample types.

**SARS-CoV-2 viral load is associated with disease severity and laboratory abnormalities.** Detectable plasma viremia was generally associated with increased disease severity among hospitalized participants, as 44% of those on a ventilator had detectable viremia compared to 19% of those receiving supplemental oxygen by nasal cannula and 0% of individuals not requiring supplemental oxygen (χ\textsuperscript{2} P = 0.006, Fig. 1b). Two of the 16 (13%) COVID-19 diagnosed outpatients were found to also have detectable SARS-CoV-2 plasma viremia, compared to none of the 74 outpatients with negative clinical nasopharyngeal testing for SARS-CoV-2 RNA and none of the 53 recovered individuals who had previously been diagnosed with COVID-19. None of the 18 plasma samples from intensive care unit participants collected in
the pre-COVID era were found to have detectable plasma SARS-CoV-2 RNA. Detectable respiratory tract SARS-CoV-2 RNA was common regardless of disease severity (Supplementary Fig. 3).

In hospitalized participants, higher plasma viral loads were significantly associated with several markers of inflammation and disease severity, including lower absolute lymphocyte counts (Spearman $r = -0.31$, $P = 0.008$), and higher levels of both C-reactive protein (CRP) ($r = 0.40$, $P = 0.0003$) and interleukin (IL)-6 ($r = 0.50$, $P < 0.0001$). Significant associations were also detected between nasopharyngeal and sputum viral loads and these three markers (Fig. 2a). When analyzed as a categorical variable, individuals with detectable plasma, nasopharyngeal or sputum viral loads had significantly lower absolute lymphocyte counts and higher CRP and IL-6 levels compared to those without detectable plasma viremia (Fig. 2b–d). Plasma, nasopharyngeal, and/or oropharyngeal viral loads were also significantly associated with increased levels of the inflammatory cytokines IL-8, IP-10, Monocyte chemoattractant protein 1 (MCP-1), interferon (IFN)-γ, and IL-1RA (Fig. 2a).

**SARS-CoV-2 viral loads and mortality risk.** Eleven participants died, all with respiratory failure listed as the primary cause of death (Supplementary Table 2). Compared to individuals who were discharged from the hospital, those who eventually died had significantly higher levels of plasma viremia at the time of initial sampling (median plasma viral load 1.0 vs 2.0 log_{10} RNA copies/mL, $P = 0.009$, Fig. 3a), which occurred a median 11 days before death. For hospitalized individuals with initial detectable viremia, 32% died vs. 8% of those without initial viremia (odds ratio (OR) 5.5, $P = 0.02$, Fig. 3e).

The majority (91%) of participants who died were receiving ventilatory support and so we performed a sensitivity analysis to assess whether plasma viremia may also predict mortality in those with the most severe disease. For participants who were on ventilatory support at the time of initial sample collection, 43% of those with detectable plasma viremia died compared to 17% of those without detectable plasma viremia, although this comparison did not reach statistical significance (OR 3.8, $P = 0.11$). The median age of those who died was significantly older than those...
Fig. 2 SARS-CoV-2 viral load is associated with markers of inflammation and disease severity. a Heat map of Spearman correlation values with bold numbers indicating P < 0.05. Absolute lymphocyte count, c-reactive protein (CRP), and interleukin-6 (IL-6) levels in hospitalized participants with and without detectable plasma (b), nasopharyngeal (c), and sputum (d) viral loads. NP nasopharyngeal, OP oropharyngeal, VL viral load. P values are from a two-tailed Wilcoxon rank sum test.
who survived (median age in those who died vs. discharged: 76 vs. 55 years, Wilcoxon P < 0.001) and a significantly greater proportion of COVID-19 patients at or over the age of 70 years died (percent died in those ≥70 vs. <70 years: 53% vs. 4%, Fisher’s exact P < 0.001). In a sensitivity analysis focused on those age ≥70 years old, 6 of 7 (86%) participants with initial plasma viremia died vs. 2 of 9 (22%) without initial viremia (OR 21, P = 0.02). Levels of SARS-CoV-2 viral load in respiratory secretions were also higher in those who eventually died (Fig. 3f–d), although the presence or absence of detectable respiratory secretion viral RNA were not significantly associated with increased risk of death (Fig. 3f–h). Logistic regression analysis was also performed with viral loads as a continuous variable and plasma, oropharyngeal, and sputum viral loads were all associated with increased risk of death (Supplementary Table 1).

A subset of hospitalized participants had longitudinal viral load measurements. Levels of plasma and respiratory viral loads declined from the first and second sampling time points in almost all participants, regardless of eventual participant outcome (Fig. 4).

Discussion

We report a comprehensive analysis of SARS-CoV-2 respiratory tract, plasma, and urine viral loads of 235 participants who were either hospitalized with COVID-19, evaluated as symptomatic outpatients, or had recovered from COVID-19 disease. The results show a relatively high prevalence of SARS-CoV-2 plasma viremia in hospitalized individuals with severe disease, but plasma viremia was also detected in symptomatic non-hospitalized participants. Levels of SARS-CoV-2 viremia was also associated with markers of inflammation and disease severity, including low lymphocyte counts, and elevated CRP and IL-6 levels. To our knowledge, this is also the first report that SARS-CoV-2 viral loads, especially detectable plasma viremia, predicted the risk of death.

In contrast to prior reports suggesting that the SARS-CoV-2 viral infection is largely confined to the respiratory and gastrointestinal tracts15,16, we were able to detect plasma viremia in a substantial proportion of both hospitalized and non-hospitalized participants. The prevalence of SARS-CoV-2 plasma viremia was lower than that found in respiratory secretions, but detectable plasma viremia had a clear relationship with concurrent clinical disease severity, lower absolute lymphocyte count, higher levels of inflammation and increased risk of death. Across the spectrum of viral infections, the extent of viral load has been a predictor of disease severity and progression, including for HIV17,18, Ebola19, influenza, and other non-COVID-19 respiratory viral infections20–22. The detection of plasma viral load has been described for both SARS-CoV-123,24 and SARS-CoV-224, but its role in pathogenesis and ability to predict clinical outcomes remains unresolved. Although we found that respiratory tract viral loads were associated with inflammation and outcomes, higher levels of SARS-CoV-2 plasma RNA had the strongest relationship with disease severity, key laboratory markers, and mortality. These results suggest that the detection and quantification of viral RNA levels may aid in the risk stratification of
Fig. 4 Longitudinal viral load measurements. Samples were obtained from plasma (a, b), nasopharyngeal swab (c, d), oropharyngeal swab (e, f), or sputum (g, h). Red dots and lines show viral loads in those who died. Two-tailed Wilcoxon signed rank test $P$ values showing significant changes over time are reported in an analysis of viral loads at the first and second available time points (TPs) from plasma ($n=13$), nasopharyngeal ($n=16$), oropharyngeal ($n=10$), sputum ($n=12$). Cps copies.
patients hospitalized with COVID-19. The associations between SARS-CoV-2 viral load with levels of CRP and IL-6 results also indicate that active viral infection could contribute to the hyperinflammatory state that is a hallmark of severe COVID-19. However, the causes of inflammation in COVID-19 could be multifactorial, especially as a subset of participants had elevated inflammatory markers without detectable plasma viremia. Additional studies are needed to determine whether antiviral treatment may effectively interrupt this pathway and whether levels of SARS-CoV-2 viral load could stratify patients into individuals who are more likely to benefit from an antiviral agent vs. those with isolated immune dysregulation, who may benefit more from an anti-inflammatory or immune-modifying agent.

The source for the plasma viremia is still not fully defined and could reflect spillage from the pulmonary tissue into the vasculature, but there is evidence that SARS-CoV-2 can also directly infect endothelial cells. Angiotensin-converting enzyme 2 is the primary receptor for SARS-CoV-2 and can be found on both arterial and venous endothelial cells, and other perivascular cells. Studies have also revealed evidence of endothelialitis with perivascular infiltration and the extrapulmonary spread of SARS-CoV-2 to other organs. Although additional infectivity studies are needed to confirm that plasma viremia represents infectious virions, these previously published support the concept that COVID-19 should be considered more than an isolated respiratory tract infection and that endothelial infection and systemic circulation of infectious SARS-CoV-2 virions may be contributing to the increases of respiratory tract infection and extrapulmonary and micro- and macrovascular complications of COVID-19 that are often disproportionate to the degree of disease severity.

There is an intense search for biomarkers of COVID-19 disease progression that could accelerate early-phase clinical studies of antiviral agents against SARS-CoV-2. There has been an expectation that respiratory tract viral shedding could serve as such a surrogate biomarker, but it is unclear if such assumptions are accurate. An example is the reported clinical benefit of remdesivir, despite the lack of evidence that remdesivir significantly reduces respiratory tract viral loads. We found only modest correlations between respiratory tract viral loads and those of the plasma. This highlights the need for additional studies to assess whether these anatomic compartments may serve as distinct sites of viral replication and whether antiviral medications might have differential effects on viral respiratory tract shedding versus plasma viremia.

Our study has a few notable limitations. First, sputum samples were obtained for only a subset of participants as many participants were unable to generate a sample. While sputum samples had the highest frequency of SARS-CoV-2 detection, this finding demonstrates a potential limitation in their use as a reliable diagnostic modality. Our longitudinal analysis of viral load changes was limited to a subset of participants due to limits on the frequency of blood draws for hospitalized individuals and early discharges in those with relatively mild disease. Additional studies of plasma viral load dynamics early in the course of disease are needed. Although this is one of the first studies to connect viral load with increased risk of mortality, the number of deaths in our study population was relatively limited and larger studies are needed to assess the role of viral load in the outpatient setting and after adjustments for potential confounding factors. Our sensitivity analysis did show that the detection of plasma viral load continued to be associated with higher mortality rates even when restricted to those with more severe disease or who were elderly.

In summary, we report that SARS-CoV-2 plasma viremia is commonly detected in hospitalized individuals but can also be detected in symptomatic non-hospitalized outpatients diagnosed with COVID-19. SARS-CoV-2 viral loads, especially within plasma, are associated with systemic inflammation, disease progression, and increased risk of death. The role of SARS-CoV-2 as a mediator of vascular and extrapulmonary COVID-19 disease manifestations should be further explored.

Methods

Participant enrollment and sample collection. We enrolled hospitalized and non-hospitalized participants with COVID-19 in a longitudinal sample collection study at Brigham and Women’s Hospital and Massachusetts General Hospital. Blood was collected from hospitalized participants diagnosed with COVID-19, non-hospitalized symptomatic individuals seeking care at a respiratory infection clinic, and participants who had recovered from known COVID-19 disease. Nasopharyngeal swabs, oropharyngeal swabs, sputum, and urine samples were collected from hospitalized participants. All samples were collected by nurses. Nasopharyngeal swabs and oropharyngeal swabs were collected in 3 mL of phosphate-buffered saline. A subset of hospitalized participants had longitudinal samples collected. Plasma obtained from a cohort of individuals in the intensive care unit from the pre-COVID-19 era were used as a comparator group. Samples were processed within 24 h of collections by the Ragon Institute and AIDS Clinical Trial Group and were subsequently stored at −80 °C. Each participant’s electronic medical record was reviewed to determine the oxygenation status (room air, on oxygen by nasal cannula, or requiring ventilator support), demographics, comorbidities and the outcome of the hospitalization (discharge or death). This study was approved by the Partners Institutional Review Board.

Ethics declaration. Informed written consent was obtained from all hospitalized participants diagnosed with COVID-19, all non-hospitalized symptomatic individuals seeking care at a respiratory infection clinic, all participants who had recovered from known COVID-19 disease, and all individuals in the intensive care unit from the pre-COVID-19 era.

Markers of inflammation and disease severity. Levels of SARS-CoV-2 viral load quantification. Levels of SARS-CoV-2 viral load were quantified using the CDC 2019-nCoV_N1 primers and probe set (Supplementary Table 3). Virions were pelleted from respiratory secretions, sputum fluids, and nasopharyngeal or oropharyngeal specimens into approximately 21,000 × g for 2 h at 4 °C. The supernatant was removed and 750 µL of TRizol-LS® Reagent (ThermoFisher) was added to the pellets and then incubated on ice. Following incubation, 200 µL of chloroform (MilliporeSigma) was added and vortexed. The mixtures were separated by centrifugation at 21,000 × g for 15 min at 4 °C, and subsequently the aqueous layer was removed and treated with an equal volume of isopropanol (Sigma). GlycolBlue™ Coprecipitant (ThermoFisher) and 100 µL 3 M Sodium Acetate (Life Technologies) were added to each sample and incubated on dry ice until frozen. RNA was pelleted by centrifugation at 21,000 × g for 45 mins at 4 °C. The supernatant was discarded and the RNA was washed with cold 70% ethanol. The RNA was resuspended in diethyl pyrocarbonate-treated water (ThermoFisher).

Each reaction contained extracted RNA, 1× TaqPath™ 1-Step RT-qPCR Master Mix, CG (ThermoFisher), the CDC N1 forward and reverse primers, and probe (Supplementary Table 3). Virions were pelleted from respiratory secretions, sputum fluids, and nasopharyngeal or oropharyngeal specimens into approximately 21,000 × g for 2 h at 4 °C. The supernatant was removed and 750 µL of TRizol-LS® Reagent (ThermoFisher) was added to the pellets and then incubated on ice. Following incubation, 200 µL of chloroform (MilliporeSigma) was added and vortexed. The mixtures were separated by centrifugation at 21,000 × g for 15 min at 4 °C, and subsequently the aqueous layer was removed and treated with an equal volume of isopropanol (Sigma). GlycolBlue™ Coprecipitant (ThermoFisher) and 100 µL 3 M Sodium Acetate (Life Technologies) were added to each sample and incubated on dry ice until frozen. RNA was pelleted by centrifugation at 21,000 × g for 45 mins at 4 °C. The supernatant was discarded and the RNA was washed with cold 70% ethanol. The RNA was resuspended in diethyl pyrocarbonate-treated water (ThermoFisher).

Each reaction contained extracted RNA, 1× TaqPath™ 1-Step RT-qPCR Master Mix, CG (ThermoFisher), the CDC N1 forward and reverse primers, and probe (Supplementary Table 3). Viral copy numbers were quantified using N1 quantitative PCR (qPCR) standards and dilution curves. The assay was run in triplicate for each sample and two non-template control wells were included as negative controls. Quantification of the Importin-8 housekeeping gene RNA level was performed to determine the quality of respiratory sample collection. An internal virology control (RCAS) was spiked into each sample and quantified to determine the efficiency of RNA extraction and qPCR amplification. Concurrent analysis of results by this CDC N1 viral load assay showed high correlation with that of the Roche cobas SARS-CoV-2 ORF-1ab and E genes (Supplementary Fig. 4).

Statistical analyses. Levels of SARS-CoV-2 viral load at the time of initial hospital collection were compared by site of sampling, disease severity and hospital outcome. SARS-CoV-2 viral load analysis was performed both as continuous variables and as a categorical variable (detectable vs undetectable) with Fisher’s exact and χ²-tests given the qualitative nature of current commercial qPCR tests. SARS-CoV-2 viral loads below 40 RNA
copies/mL were categorized as undetectable and set at 1.0 log_{10} RNA copies/mL. For the subset of participants with repeated sampling, the sign test was used to assess viral load change between the first and second time point. Correlation analysis was performed using Spearman rank-based testing. In the correlation analysis between the soluble inflammatory markers and viral load, a p-value <0.01 between a marker and any of the viral load measurements was the threshold to include that marker in the reported results. Logistic regression and other statistical analyses were performed using GraphPad Prism 8 and SAS software, version 9.4. Only univariate analysis was performed due to the available sample size, but we did perform sensitivity analysis for plasma viral load effects based on disease severity and age.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
The authors declare that the data supporting the findings of this study are available within the article and its Supplementary Data. Source data are provided with this paper.

Received: 15 July 2020; Accepted: 22 September 2020; Published online: 30 October 2020

References
1. Cheng, V. C. et al. Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome. Clin. Infect. Dis. 38, 467–475 (2004).
2. Hung, I. F. et al. Viral loads in clinical specimens and SARS manifestations. Emerg. Infect. Dis. 10, 1550–1557 (2004).
3. To, K. K. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(20)30196-1 (2020).
4. Xu, K. et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa351 (2020).
5. He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. https://doi.org/10.1038/s41591-020-0869-5 (2020).
6. Wu, J. T. et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat. Med. 26, 506–510 (2020).
7. Guan, W. J. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2002302 (2020).
8. Li, R. et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science https://doi.org/10.1126/science.abb3221 (2020).
9. Oxley, T. J. et al. Large-vessel stroke as a presenting feature of covid-19 in the young. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2009787 (2020).
10. Menter, T. et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variigated findings of lungs and other organs suggesting vascular dysfunction. Histopathology https://doi.org/10.1111/his.14134 (2020).
11. Ackermann, M. et al. Pulmonary vascular endothelitis, thrombosis, and angiogenesis in covid-19. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2005432 (2020).
12. Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. https://doi.org/10.1016/S0140-6736(20)30937-5 (2020).
13. Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. https://doi.org/10.1016/j.chom.2020.04.009 (2020).
14. Chen, X. et al. Detectable serum SARS-CoV-2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 (IL-6)-level in critically ill COVID-19 patients. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa449 (2020).
15. Wang, W. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. https://doi.org/10.1001/jama.2020.3788 (2020).
16. Wöffel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature. https://doi.org/10.1038/s41586-020-2196-x (2020).
17. Mellors, J. W. et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167–1170 (1996).
18. Saag, M. S. et al. HIV viral load markers in clinical practice. Nat. Med. 2, 625–629 (1996).
19. Towner, J. S. et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J. Virol. 78, 4330–4341 (2004).
20. Vos, L. M. et al. Lower respiratory tract infection in the community: associations between viral aetiology and illness course. Clin. Microbiol. Infect.. https://doi.org/10.1016/j.cmi.2020.03.023 (2020).
21. Li, C. C. et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg. Infect. Dis. 16, 1265–1272 (2010).
22. Lee, N. et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J. Infect. Dis. 200, 492–500 (2009).
23. Grant, P. R. et al. Detection of SARS coronavirus in plasma by real-time RT-PCR. N. Engl. J. Med. 349, 2468–2469 (2003).
24. Wang, W. K. et al. Detection of severe acute respiratory syndrome coronavirus RNA in plasma during the course of infection. J. Clin. Microbiol. 43, 962–965 (2005).
25. Blanco-Melo, D. et al. Balanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045 e1039 (2020).
26. Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631–637 (2004).
27. Chen, L., Li, X., Chen, M., Feng, Y. & Xiong, C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc. Res. 116, 1097–1100 (2020).
28. Puelles, V. G. et al. Multigorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2011400 (2020).
29. Towner, J. S. et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb. Haemost. https://doi.org/10.1055/s-0040-1710018 (2020).
30. Ranucci, M. et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J. Thromb. Haemost. https://doi.org/10.1111/jth.14854 (2020).
31. Bikdeli, B. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J. Am. Coll. Cardiol. https://doi.org/10.1016/j.jacc.2020.04.031 (2020).
32. Zhang, Y. et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N. Engl. J. Med. 382, e38 (2020).
33. Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 - preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2007764 (2020).
34. Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569–1578 (2020).
35. Boudreault, F. et al. Zinc deficiency primes the lung for ventilator-induced injury. JCI Insight 2. https://doi.org/10.1172/jci.insight.86507 (2017).
36. Centers for Disease Control and Prevention (CDC). Accessed April 2020.
37. Palmer, S. et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41, 4531–4536 (2003).

Acknowledgements
We thank the participants of this trial and the dedicated clinical staff who cared for them. We appreciate the support of the Ragon Institute of MGH, MIT, and Harvard, the Massachusetts General Hospital Translational and Clinical Research Center, the Brigham and Women’s Hospital Center for Clinical Investigation and the Partners Biobank.

Financial support
This study was supported in part by the Massachusetts Consortium for Pathogen Readiness through grants from the Evergreen Fund, Mark, Lisa, and Emid Schwartz (J.Z.L. and X.Y.); Nancy Zimmerman (to G.A.); NIH grants U01AI106701 (to J.Z.L.), by the Harvard University Center for AIDS Research (NIAID 5P30AI060354), 3R37AI080289 (to G.A.), CDC grant U01CK000490 (to E.T.R.), the SAMANA Kay MGH Scholar program (to G.A.), and a Clinical Investigator Award from National Heart, Lung and Blood Institute, K08HL141694 (to D.H.).

Author contributions
J.F., R.K., H.C., G.A., B.D.W., Y.L., N.J., D.H., and J.Z.L. contributed to participant recruitment, sample collection, sample processing, and clinical data collection. All authors reviewed the manuscript.

Competing interests
J.Z.L. has consulted for Abbvie and Jan Biotech. G.A. is the founder of Seromyx Inc. All other authors declare no competing interests.
The Massachusetts Consortium for Pathogen Readiness
Betelihem A. (Betty) Abayneh3, Patrick Allen3, Diane Antille3, Alejandro Balazs2,3, Julia Bals2,3, Max Barbash2,3, Yannic Bartsch2,3, Julie Boucau2,3, Siobhan Boyce3, Joan Braley3, Karen Branch3, Katherine Broderick3, Julia Carney3, Josh Chevalier2,3, Manish C. Choudhary1, Navin Chowdhury2,3, Trevor Cordwell1, George Daley5, Susan Davidson3, Michael Desjardins1, Lauren Donahue1, David Drew3, Kevin Einkauf2,3, Sampson Elizabeth1, Ashley Elliman3, Behzad Etemad1, Jon Fallon2,3, Liz Fedirko2,3, Kelsey Finn2,3, Jeanne Flannery3, Pamela Forde3, Pilar Garcia-Broncano2,3, Elise Gettings3, David Golan5, Kirsten Goodman1, Amanda Griffin3, Sheila Grimmel3, Kathleen Grinke3, Ciputra Adjayana Hartana2,3, Meg Healy3, Howard Heller3,5, Deborah Henault3, Grace Holland3, Chenyang Jiang2,3, Hannah Jordan1, Paulina Kaplon2,3, Elizabeth W. Karlson1, Marshall Karpell2,3, Chantal Kayitesi3, Evan C. Lam2,3, Vlasta LaValle3, Kristina Lefteri2,3, Xiaodong Lian2,3, Mathias Lichterfeld1,3, Daniel Lingwood2,3, Hang Liu2,3, Jinqing Liu2,3, Kell Lopez1, Yuting Lu3, Sarah Luthern3, Ngoc L. Ly2,3, Maureen MacGowan1, Karen Magispoc1, Jordan Marchewka3, Brittani Martin3, Roseann McNamara3, Ashlin Micheli2,3, Ilan Millstrom2,3, Noah Miranda2,3, Christian Nambu3, Susan Nelson3, Marjorie Noone3, Lewis Novack1, Claire O’Callaghan2,3, Christine Omerborn3, Matthew Osborn2,3, Lois Chris Pacheco3, Nicole Phan3, Shiv Pilla2,3, Falisha A. Porto3, Yelizaveta Rassadkina2,3, Alexandra Reissie2,3, Francis Ruzicka2,3, Kyra Seiger2,3, Kathleen Selleck3, Libera Sessa2,3, Arlene Sharpe5, Christianne Sharr2,3, Sally Shin2,3, Nishant Singh2,3, Sue Slaughenhaupt3, Kimberly Smith Sheppard3, Weiwei Sun2,3, Xiaoming Sun2,3, Elizabeth (Lizzie) Suschana3, Opeyemi Talabi1, Hannah Ticheli2,3, Scott T. Weiss1, Vivine Wilson3 & Alex Zhu2,3

5Harvard Medical School, Boston, MA, USA.